An analysis compares Pfizer Inc. (PFE) and BioNTech SE (BNTX) to determine which pharmaceutical giant is better positioned for the market and healthcare landscape in the post-COVID era.

Pfizer Inc. (PFE) is highlighted as a top dividend stock by hedge funds, coinciding with a significant FDA milestone for its drug Ibrance.

Pfizer Inc. (PFE) CEO Albert Bourla provides his take on the company's current standing and future outlook.

Pfizer Inc. (PFE) stock is identified as one of the best and safest investment options for beginner investors.

Analysts are providing their outlook on where Pfizer Inc. (PFE) is headed, offering insights into its future performance.

Pfizer Inc. published its Q2 2026 earnings call summary, reporting on its financial performance and business updates for the second quarter.

An analysis evaluates whether Pfizer Inc. (PFE) is currently a good stock to buy, providing insights into its investment potential.

Pfizer Inc. (PFE) is reportedly expanding its cancer pipeline through a landmark partnership with Innovent. This collaboration aims to strengthen Pfizer's presence in oncology research and development.

CICC has begun its coverage of pharmaceutical giant Pfizer Inc. (PFE) with an 'Outperform' rating, signaling a positive outlook for the company's stock.

Pfizer Inc. (PFE) is being highlighted as one of Goldman Sachs' top healthcare stock picks, suggesting strong investment potential.

An analysis comparing Pfizer Inc. and Eli Lilly and Company from an investment perspective, focusing on growth versus value plays in the pharmaceutical sector.

A Pfizer Inc. executive has claimed that China is now surpassing Europe in the fields of drug innovation and development. This assessment highlights a shift in the global pharmaceutical landscape.

Analysts are evaluating BP and Cheniere Energy (LNG) as potential top LNG stocks to buy in 2026, while also considering Pfizer Inc. (PFE) among the best medical stocks for investment according to billionaires. These assessments provide insights into future investment opportunities in the energy and pharmaceutical sectors.

Pfizer Inc. has announced positive topline results from its Phase 3 TALAPRO-3 study of TALZENNA®, indicating successful outcomes for the drug.

Pfizer Inc. and Astellas Pharma have announced positive results from their Phase 3 EV-304 clinical trial for the drug PADCEVTM.